Drawing for I-BODY

USPTO serial 79368363

I-BODY

Reviewed by CopyMark Law Group

Reg. 8428197Status 700Registered
Filing date
Status date
Registration date
Sep 15, 2026
Examiner
MCDOWELL, MATTHEW J
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with I-BODY?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Cheryl L. Burbach

Cheryl L. Burbach Erise IP, P.A.7015 College Boulevard, Suite 700Overland Park, KS 66211United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical, biotechnology and medical preparations and substances for medical use or purposes, namely, pharmaceutical preparations for the treatment of fibrosis, cancer and other diseases, biological preparations for the treatment of fibrosis, cancer and other diseases; Pharmaceutical, biotechnology and medical preparations and substances for medical use or purposes, namely, prescription injectable pharmaceutical preparations for the treatment of fibrosis, cancer and other diseases, prescription injectable biological preparations for the treatment of fibrosis, cancer and other diseases, inhaled pharmaceutical preparations for the treatment of fibrosis, cancer and other diseases, inhaled biological preparations for the treatment of fibrosis, cancer and other diseases; diagnostic preparations and reagents for medical purposes; antibodies for medical purposes; antibody fragments for medical purposes; antibody fragments for combining with other chemicals, proteins and cells for medical or diagnostic purposes; antibody conjugates for medical purposes; immunological antibodies for medical use; monoclonal antibodies for medical diagnostic use; monoclonal antibodies for medical use; monoclonal antibodies for therapeutic purposes; preparations containing antibodies for use in medicine; proteins for medical use in binding antibodies; proteins for medical use in detecting antibodies; reagents for medical research use in the development of monoclonal antibodies for medical purposes; molecular targets for drug and vaccine development, all in the nature of biological reagents for medical research use; tagged antibodies for medical research and medical use; vaccines; vaccines against cancer viral or bacterial infection; vaccines for human use; vaccine adjuvants; diagnostic preparations, reagents, substances, products and testing materials for medical purposes, namely, for capturing, imaging, detecting, identifying or characterising protein and cell therapeutic candidates; reagents for use in diagnostic tests for medical purposes; reagents for medical research applications for medical diagnosis; biological tissue, namely, recombinant human protein production cell line for medical use or modified human cells for therapeutic use; biological tissue, namely recombinant human protein production cell line for modified human cells for therapeutic use; proteins for medical use in recombinant DNA technology; biological reagents for use in molecular biology for medical purposesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 15, 2026NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Sep 15, 2026R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jul 28, 2026NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jul 28, 2026PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 23, 2026GPNXNOTIFICATION PROCESSED BY IB—
Jul 22, 2026NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 8, 2026OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jul 8, 2026OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Jun 26, 2026CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 31, 2026RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Apr 28, 2026TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Apr 28, 2026ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 28, 2026REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Apr 28, 2026CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Apr 28, 2026COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Oct 28, 2025RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Oct 27, 2025RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Apr 24, 2025RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Apr 20, 2025RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Oct 12, 2024OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Sep 25, 2024OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Sep 25, 2024OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Sep 13, 2024GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Sep 13, 2024GNSLLETTER OF SUSPENSION E-MAILED—
Sep 13, 2024CNSLSUSPENSION LETTER WRITTEN—
Jul 22, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 22, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 22, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 19, 2024RFNTREFUSAL PROCESSED BY IB—
Jan 29, 2024RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jan 29, 2024RFRRREFUSAL PROCESSED BY MPU—
Jan 12, 2024RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jan 11, 2024CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 30, 2023DOCKASSIGNED TO EXAMINER—
May 2, 2023MAFRAPPLICATION FILING RECEIPT MAILED—
Apr 28, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 27, 2023REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance